Vivo Infusion has announced the acquisition of Infusion Associates, significantly expanding its operational footprint in the US.

The companies have not disclosed the financial details of the transaction.

As part of this acquisition, Vivo Infusion will now be responsible for overseeing around 80 ambulatory infusion centres spread across 15 states in the US.

Established in 2001, Infusion Associates has experienced growth through new centre openings and strategic acquisitions, particularly in the Midwest.

It has centres across various US states, including Michigan, Ohio, Minnesota, and Wisconsin.

Infusion Associates has developed a distinctive operating model that encompasses physician partnerships as well as a clinical trials division, thereby enhancing its service offerings to patients, pharmaceutical partners, and payors. 

Post-acquisition, Vivo Infusion is poised for continued expansion in the Midwest region of the US, with plans for additional de novo centre buildouts.

Vivo Infusion CEO Chris Reef said: “Infusion Associates brings several unique capabilities to Vivo’s growing business which will continue to strengthen our relationships with our patients, payors and pharma partners. We are delighted to partner with the entire team.”

Since 2021, InTandem Capital Partners, which is a private equity company specialising in healthcare services, has been a capital partner and key investor in Vivo Infusion.

In relation to the acquisition of Infusion Associates, Vivo Infusion said that InTandem has secured nearly $150m of additional equity capital from its limited partners.

This funding is intended to support Vivo Infusion's growth strategy throughout the country for the remainder of the current year and beyond.

TripleTree acted as the exclusive financial adviser to Infusion Associates during the latest deal.